Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis

Noninvasive tests to diagnose and monitor the progression of neurodegenerative disorders have been a challenge for decades. The aim of this study was to explore the feasibility of applying liquid biopsy procedures to patients with a neurodegenerative disease such as amyotrophic lateral sclerosis (AL...

Descripción completa

Detalles Bibliográficos
Autores principales: Mendioroz, Maite, Martínez‐Merino, Leyre, Blanco‐Luquin, Idoia, Urdánoz, Amaya, Roldán, Miren, Jericó, Ivonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989775/
https://www.ncbi.nlm.nih.gov/pubmed/29928659
http://dx.doi.org/10.1002/acn3.565
Descripción
Sumario:Noninvasive tests to diagnose and monitor the progression of neurodegenerative disorders have been a challenge for decades. The aim of this study was to explore the feasibility of applying liquid biopsy procedures to patients with a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS). We isolated plasma cell‐free DNA (cfDNA) in 20 ALS patients and 20 controls and used cfDNA to identify a novel differentially methylated mark in RHBDF2 gene in ALS patients compared to controls. Our findings support the notion that liquid biopsy may be applied to living patients as a source of potential epigenetic biomarkers for neurodegenerative disorders.

Ejemplares similares